X4 Pharmaceuticals, Inc.
XFOR
$3.18
$0.3813.57%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -93.15% | 1,908.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -93.15% | 1,908.86% | |||
| Cost of Revenue | -93.09% | 1,461.59% | |||
| Gross Profit | -93.16% | 2,028.18% | |||
| SG&A Expenses | -36.58% | -0.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.26% | 2.96% | |||
| Operating Income | -177.79% | 73.56% | |||
| Income Before Tax | -8,234.18% | 100.80% | |||
| Income Tax Expenses | 8.82% | -86.82% | |||
| Earnings from Continuing Operations | -9,228.01% | 100.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9,228.01% | 100.71% | |||
| EBIT | -177.79% | 73.56% | |||
| EBITDA | -188.58% | 74.70% | |||
| EPS Basic | -8,528.16% | 100.70% | |||
| Normalized Basic EPS | -7,598.62% | 100.79% | |||
| EPS Diluted | -8,781.00% | 100.68% | |||
| Normalized Diluted EPS | -7,624.65% | 100.79% | |||
| Average Basic Shares Outstanding | 8.38% | 1.12% | |||
| Average Diluted Shares Outstanding | 7.92% | 1.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||